Unlocking the potential of human Natural Killer cells.
Cancer Treatment Reimagined
About Us
NK:IO reimagines cancer treatment. By harnessing the potential of the innate immune system, we are developing ground breaking NK cell and small molecule therapies targeting both haematological and solid tumours.
Our technologies are built on pioneering research carried out by Hugh Brady and Matthew Fuchter at Imperial College, London. Based on their discoveries we have developed three interrelated, proprietary technology platforms.
Changing the Future of Cancer Immunotherapy
This video shows...... Lorem ipsum dolor sit amet consectetur adipiscing elit molestie fermentum, congue vulputate felis montes massa proin fusce nisi convallis, nunc semper lacus sagittis eleifend mollis urna malesuada. Taciti rutrum per iaculis curabitur mi pretium venenatis praesent, risus dictumst. Ac lacus enim class molestie justo luctus pellentesque etiam non eu vulputate posuere tincidunt eleifend, sodales tempus euismod quis id ornare potenti netus suspendisse lacinia et sem.
Our Platform Technologies
Exploiting our pioneering discoveries in small molecule and peptide ligand activation of blood stem cell progenitors, NK:IO’s platform technologies offer the potential for greatly enhanced NK cell expansion and tumour killing capacity in the field of NK cell-based therapy for cancer.
Our Partners and Investors
UKI2S
The UK Innovation & Science Seed Fund (UKI2S) is an impact fund, supporting the most ambitious UK innovators from startup to series A and beyond.
Start Codon
Start Codon supports aspiring entrepreneurs to spin out and/or help in the development and commercialisation of their disruptive innovations.
Meltwind
Meltwind is the due diligence and portfolio management team for Jonathan Milner who invests as an Angel across the life sciences, supporting early-stage companies.
Imperial College London
Imperial is a global top ten university with a world-class reputation in science, engineering, business and medicine.
Wren Capital
Wren Capital is an angel investor in science, engineering and software.